Silver or silver nanoparticles: A hazardous threat to the environment and human health?

Journal of Applied Biomedicine

Volumn 6, Issue 3, 2008, Pages 117-129

  Panyala, Nagender Reddy ^a   Peña Méndez, Eladia María ^b   Havel, Josef ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

Antimicrobial activity; Argyria; Argyrosis; Silver nanoparticles; Silver toxicity

Indexed keywords

ASBESTOS; COLDARGAN; NANOMATERIAL; NANOPARTICLE; SILVER; SILVER NITRATE; SILVER PROTEIN; SULFADIAZINE SILVER; UNCLASSIFIED DRUG; VASOCONSTRICTOR AGENT;

AGYRIA; ALLERGIC RHINITIS; AQUATIC ENVIRONMENT; ARGYRIA; BANDAGE; COLON CANCER; CONTACT DERMATITIS; DANDRUFF; DRUG HYPERSENSITIVITY; DUST EXPOSURE; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL STRESS; ERYTHEMA MULTIFORME; EYE IRRITATION; EYE TOXICITY; GASTROINTESTINAL TOXICITY; HEALTH HAZARD; HUMAN; LIVER TOXICITY; NANOMEDICINE; NANOTECHNOLOGY; NEPHROTOXICITY; NONHUMAN; PARTICLE SIZE; RESPIRATORY TRACT DISEASE; REVIEW; SKIN ALLERGY; SKIN DISCOLORATION; SKIN IRRITATION; SOIL POLLUTION; SYSTEMIC DISEASE;

EID: 56549119606     PISSN: 1214021X     EISSN: 12140287     Source Type: Journal    
DOI: 10.32725/jab.2008.015     Document Type: Review

References (95)

1. Aaseth J, Olsen A, Halse J, Hovig T: Argyria-tissue deposition of silver as selenide. Scand. J. Clin. Lab. Invest. 41:247-251, 1981.
2. Albright LJ, Wilson EM: Sub-lethal effects of several metallic salt-organic compounds combinations upon heterotrophic microflora of a natural water. Water Res. 8:101-105. 1974.
3. Alt V, Bechert T, Steinrucke P, Wagener M, Seidel P, Dingeldein E, Domann E, Schnettler R: An in vitro assessment of the antibacterial properties and cytotoxicity of nanoparticulate silver bone cement. Biomaterials 25:4383-4391, 2004.
4. Armitage SA, White MA, Wilson HK: The determination of silver in whole blood and its application to biological monitoring of occupationally exposed groups. Ann. Occup. Hycy. 40:331-338, 1996.
5. Baldi C, Minoia C, Di Nucci A, Capodaglio E, Manzo L: Effects of silver in isolated rat hepatocytes. Toxicol. Lett. 41:261-269, 1988.
6. Bianchi L, Orlandi A, Di Stefani A, Ricci R, Chimenti S: "Familial" generalized argyria. Arch. Dermatol. 142:789-90, 2006.
7. Bogle KA, Dhole SD, Bhoraskar VN: Silver nanoparticles:synthesis and size control by electron irradiation. Nanotechnology 17:3204-3208, 2006.
8. Boosalis MG, McCall JT, Ahrenhalz DH, Solem LH, McClain CJ: Serum and urinary silver levels in thermal injury patients. Surgery 101:40-43. 1987.
9. Borm PJ and Kreyling WJ: Toxicological hazards of inhaled nanoparticles-potential implications for drug delivery. J. Nanosci. Nanotechnol. 4:521-551, 2004.
10. Bouts BA: Images in clinical medicine. Argyria. N. Engl. J. Med. 340:1554, 1999.
11. Brandt D, Park B, Hoang M, Jacobe HT: Argyria: secondary to ingestion of homemade silver Solution. J. Am. Acad. Dermatol. 53:S105-S107. 2005.
12. Braydich-Stolle L, Hussain S, Schlager JJ, Hofmann MC: In vitro, cytotoxicity of nanoparticles in mammalian germline stem cells. Toxicol. Sci. 88:412-419, 2005.
13. Breitstadt R: Occupational exposure limits for metallic silver. In Proc. 2nd European Precious Metals Conference, Lisbon, Port gal 1995, pp. 1-13.
14. Brooks SM: Lung disorders resulting from the inhalation of metals. Clin. Chest Med. 2:235-254, 1981.
15. Buckley WR, Oster CF, Fasset DW: Localized argyria II. Chemical nature of the silver containing particles. Arch. Dematol. 92:697-705, 1965.
16. Burd A, Kwok CH, Hung SC, Chan HS, Gu H, Lam WK, Huang L: A comparative study of the cytotoxicity of silver-based dressings in monolayer cell, tissue explant, and animal models. Wound Repair Regen. 15:94-104, 2007.
17. Catsakis LH, Sulica VI: Allergy to silver amalgams. Oral Surg. Oral Med. Oral Pathol. 46:371-5, 1978.
18. Chang ALS, Khosravi V, Egbert B: A case of argyria after colloidal silver ingestion. J. Cutan. Pathol. 33:809-811, 2006.
19. Chen X, Schluesener HJ: Nanosilver:A nanoproduct in medical application. Toxicol. Lett. 176:1-12, 2007.
20. Cheng D, Yang J. Zhao Y: Antibacterial materials of silver nanoparticles application in medical appliances and appliances for daily se. Chin. Med. Equip. J. 4:26-32. 2004.
21. Dietl HW, Anzil AP, Mehraein P: Brain involvement in generalized argyria. Clin. Neuropathol. 3:32-38, 1984.
22. Drake PL, Hazelwood KJ: Exposure-related health effects of silver and silver compounds: A Review. Ann. Occup. Hyg. 49:575-585, 2005.
23. Eisler R.: A review of silver hazards to plants and animals. In Andren AW, Bober TW. (eds.): Proc. 4th Int. Conf. Transport, Fate and Effects of Silver in the Environment, Madison, Wisconsin 1996, pp. 143-144.
24. Elechiguerra JL, Burt JL, Morones JR, Camacho-Bragado A, Gao X, Lara HH, Yacaman MJ: Interaction of silver nanoparticles with HIV-1. J. Nanobiotechnology 3: art. No. 6, 2005.
25. Espinal ML, Ferrando L, Jimenex DF: Asymptomatic blue nervus-like macule. Diagnosis: localized argyria. Arch. Dermatol. 132:461-464, 1996.
26. Fisher NM, Marsh E, Lazova R: Scar-localized argyria secondary to silver sulfadiazine cream. J. Am. Acad. Dermatol. 49:730-732, 2003.
27. Flegal AR, Davis JA, Connor MS, Conaway CH: Sources, transport, fate, and toxicity of pollutants in the San Francisco Bay estuary. J. Environ. Res. 105:0-4, 2007.
28. Fung MC, Bowen DL: Silver products for medical indications: risk-benefit assessment. J. Toxicol. Clin. Toxicol. 34:119-126, 1996.
29. Furchner JE, Richmond CR, Drake GA: Comparative metabolism of radionuclides in mammals-IV. Retention of silver-110m in the mose, rat, monkey and dog. Health Phys. 15:505-14, 1968.
30. Gopinath P, Gogoi SK, Chattopadhyay A, Gosh SS: Implications of silver nanoparticle induced cell apoptosis for invitro gene therapy. J. Nanobiotechnoogy 19: art. No. 075104, 2008.
31. Graham SA, O'Meara JM: The feasibility of measuring silver concentrations in vivo with x-ray fluorescence. Phys. Med. Biol. 49:N259-266, 2004.
32. Greene RM, Su WPD: Argyria. Am. Fam. Physician 36:151-154, 1987.
33. Gulbranson SH, Hud JA, Hansen RC: Argyria following the se of dietary supplements containing colloidal silver protein. Cutis 66:373-376, 2000.
34. Hill WR, Pillsbury DM: Argyria: The Pharmacology of Silver. MD:Williams & Wilkins Company, Baltimore 1939.
35. Hogstrand C, Wood CM. The toxicity of silver to marine fish. In Andren AW, Bober TW (eds.): Proc. 4th Int. Conf. Transport, Fate and Effects of Silver in the Environment. Madison. Wisconsin 1996. pp. 109-112.
36. Hussain SM, Hess KL, Gearhart JM, Geiss KT, Schlager JJ: In vitro toxicity of nanoparticles in BRL 3A rat liver cells. Toxicol. in Vitro 19:975-983, 2005.
37. Hussain SM, Javorina. MK, Schrand AM, Duhart HM, Ali SF, Schlager JJ: The interaction of manganese nanoparticles with PC-12 cells induces dopamine depletion. Toxicol. Sci. 92:456-463, 2006.
38. Johnston AM, Memon AA: A Medical Mystery. N. Engl. J. Med. 340:1011, 1999.
39. Jose RM., Jose LE, Alejandra C, Katherine H, Juan BK, Jose TR, Miguel JY: The bactericidal effect of silver nanoparticles. Nanotechnology 16:2346-2353, 2005.
40. Kaewamatawong T, Shimada, A, Okajima A, Inoue H, Morita T, Inoue K, Takano H.: Acute and subacute pulmonary toxicity of low dose of ultrafine colloidal silica particles in mice after intratracheal instillation. Toxicol. Pathol. 34:958-965, 2006.
41. + permeability in the renal proximal tubule: Reversal by thiol reagents. J. Membr. Biol. 102:11-19. 1988.
42. 3. J. Dermatol. 21:50-53, 1994.
43. Legat FJ, Goessler W, Schlagenhaufen C, Soyer HP: Argyria after short-contact acupuncture. Lancet 352:241, 1998.
44. Limbach LK, Wick P, Manser P, Grass RN, Bruinink A, Stark WJ: Exposure of engineered nanoparticles to human lung epithelial cells: Influence of chemical composition and catalytic activity on oxidative stress. Environ. Sci. Technol. 41:4158-4163, 2007.
45. Lippmann M, Yeates DB, Albert RE: Deposition, retention, and clearance of inhaled particles. Br. J. Ind. Med. 37:337-362, 1980.
46. Loeffler KU, Lee WR: Argyrosis of the lacrimal sac. Graefe's Arch. Clin. Exp. Ophthalmol. 225: 146-150, 1987.
47. Lok CN, Ho CM, Chen R, He QY, Yu WY, Sun H, Tam PK, Chiu JF, Che CM: Proteomic analysis of the mode of antibacterial action of silver nanoparticles. J. Proteome Res. 5:916-924, 2006.
48. Margaret IP, Lui SL, Poon VKM, Lung I, Burd A: Antimicrobial activities of silver dressings: an in vitro comparison. J. Med. Microbiol. 55:59-63, 2006.
49. Marshall JP II, Schneider RP: Systemic argyria secondary to topical silver nitrate. Arch. Dermatol. 113:1077-1079, 1977.
50. McAuliffe ME. Perry MJ: Are nanoparticles potential male reproductive toxicants? A literature review. Nanotoxicology 1:204-21O, 2007.
51. Menaguale G, Fazio R, Fazio M: Argyria: A case following the prolonged use of a rhinologic drug. Esper. Dermatol. (Roma) 4:299-303, 2003.
52. Morones JR, Elechiguerra JL, Camacho A, Holt K, Kouri JB, Ramirez JT, Yacaman MJ: The bactericidal effect of silver nanoparticles. J. Nanotechnology 16:2346-2353, 2005.
53. Murata T, Kanao-koshikawa M, Takamatsu T: Effects of Pb, Cu, Sb, In and Ag contamination on the proliferation of soil bacterial colonies, soil dehydrogenase activity, and phospholipid fatty acid profiles of soil microbial communities. Water, Air Soil Pollut. 164:103-118, 2005.
54. Nordberg G, Gerhardsson LS: Silver. In Seffer HG, Sigel H, Sigel A (eds.): Handbook on Toxicity of Inorganic Compounds. Marcell Dekker, New York 1988, pp. 619-624.
55. Ogden JS, Bogdanchikova NE, Corker JM, and Petranovskii VP: Structure of silver clusters embedded in erionite channels. Eur. Phys. J. D 9:605-608, 1999.
56. Padlewska K, Schwartz R: Argyria. In Khan S, Vinson, RP, Miller JJ, Gelfand, James, WD, Gross PR (eds): eMedicine: Dermatology and Online Medical Reference 2007. eMedicine.com, Inc., 0maha, NE 2007 (http://www.emedicine.com)
57. Pariser RJ: Generalized argyria. Clinicopathologic features and histochemical studies. Arch. Dermatol. 114:373-380, 1978.
58. Phalen RF, Morrow PE: Experimental inhalation of metallic silver. Health Phys. 24:509-518, 1973.
59. Prescott RJ, Wells S: Systemic argyria. J. Clin. Pathol. 47:556-557, 1994.
60. Pyatenko A, Shimokawa K, Yamaguchi M: Synthesis of silver nanoparticles by laser ablation in pure water. J. Appl. Phys. A: Mater. Sci. Proces. A79:803-806, 2004.
61. Robinson-Bostom L, Pomerantz D, Wilkel C, Mader R, Lerner L, Dufresne R, Flotte T: Localized argyria with pseudo-ochronosis. J. Am. Acad. Dermatol. 46:222-229, 2002.
62. Rongioletti F, Robert E, Buffa P, Bertagno R, Rebora A: Blue nevi-like dotted occupational argyria. J. Am. Acad. Dermatol. 27:1015-1016, 1992.
63. Rosenman KD, Seixas N, Jacobs I: Potential nephrotoxic effects of exposure to silver. Br. J. Ind. Med. 44:267-272, 1987.
64. Rosenman KD, Moss A, Kon S: Argyria: clinical implications of exposure to silver nitrate and silver oxide. J. Occup. Med. 21:430-435, 1979.
65. Rungby J, Danscher G: Localization of exogenous silver in brain and spinal cord of silver exposed rats. Acta Neuropathol. 60:91-98, 1983a.
66. Rungby J, Danscher G: Neuronal accumulation of silver in brains of progeny from argyric rats. Acta Neuropathol. 61:258-262, 1983b.
67. Saint S, Veenstra DL, Sullivan SD, Chenoweth C, Fendrick AM: The potential clinical and economic benefits of silver alloy urinary catheters in preventing urinary tract infection. Arch. Intern. Med. 160:2670-2675, 2000.
68. Samuel U, Guggenbichler JP: Prevention of catheter-related infections: the potential of a new nano-silver impregnated catheter. Int. J. Antimicrob. Agents 23S1:S75-S78, 2004.
69. Sarkar S, Jana AD, Samanta SK, Mostafa G: Facile synthesis of silver nano particles with highly efficient anti-microbial property. Polyhedron 26:4419-4426, 2007.
70. Sato S, Sueki H, Nishijima A: Two unusual cases of argyria: the application of an improved tissue processing method for X-ray microanalysis of selenium and sulphur in silver-laden granules. Br. J. Dermatol. 140:158-163. 1999.
71. Scott KG, Hamilton JG: The metabolism of silver in the rat with radiosilver used as an indicator. Publ. Pharmacol. 2:241-262, 1950.
72. Senjen R: Nano silver - a threat to soil. water and human health? Friends of the Earth Australia March 2007. Available at: http://nano.foe.org.au/node/189.
73. Sergeev MB, Kasaikin AV, Litmanovich AE: Cryochemical synthesis and properties of silver nanoparticle dispersions stabilised by poly(2-dimethylaminoethyl methacrylate). Mendeleev Commun. 9:130-132, 1999.
74. Seung-heon S, Mi-kyung Y, Jeung-kyu K: The effects of nano-silver on the proliferation and cytokine production in peripheral blood mononuclear cells. Jpn. J. Rhinol. 45:269, 2006.
75. Sharma CS, Sarkar S, Periyakaruppan A, Barr J, Wise K, Thomas R, Wilson BL, Ramesh GT: Single-walled carbon nanotubes induces oxidative stress in rat lung epithelial cells. J. Nanosci. Nanotechnol. 7: 2466-2472. 2007.
76. Shelley WB, Shelley ED, Burmeister V: Argyria: the intradermal "photograph", a manifestation of passive photosensitivity. J. Am. Acad. Dermatol. 16:211-217, 1987.
77. Shin SH, Ye MK, Kim HS, Kang HS: The effects of nano-silver on the proliferation and cytokine expression by peripheral blood motion clear cells. Int. Immunopharmacol. 7:1813-1821, 2007.
78. Soto KF, Carrasco A, Powell TG, Garza KM, Murr LE: Comparative in vitro cytotoxicity assessment of some manufactured nanoparticulate materials characterized by transmission electron microscopy. J. Nanoparticle Res. 7:145-169, 2005.
79. Soto KF, Murr LE, Garza KM: Cytotoxic Responses and Potential Respiratory Health Effects of Carbon and Carbonaceous Nanoparticulates in the Paso del Norte Airshed Environment. Int. J. Environ. Res. Public Health 5:12-25, 2008.
80. Staudt C, Heinrich R, Wucher A: Formation of large clusters during sputtering of silver. Nucl. Istrum. Methods Phys. Res. B: 164-165, 677-686, 2000.
81. Sue YM, Lee JY, Wang MC, Lin TK, Sung JM, Huang JJ: Generalized argyria in two chronic hemodialysis patients. Am. J. Kidney Dis. 37:1048-1051, 2001.
82. Sun Y, Xia Y: Shape controlled synthesis of gold and silver nanoparticles. Science 298:2176-2179, 2002.
83. Takenaka S, Karg E, Roth C, Schulz H, Ziesenis A, Heinzmann U, Schramel P, Heyder J: Pulmonary and systemic distribution of inhaled ultra fine silver particles in rats. Environ. Health Perspect. 4:547-551, 2001.
84. +) reduces denitrification and induces enrichment of novel nirK genotypes in soil. FEMS Microbiol. Lett. 270:189-194. 2007.
85. Tomi NS, Kranke B, Aberer W: A silver man. Lancet 363: 532, 2004.
86. Venugopal B, Luckey TD (eds.): Metal toxicity in mammals. In Chemical Toxicology of Metals and Metalloids. Academic Press, New York 1978, pp. 32-36.
87. Watanabe K: Histopathological study of damage to periodontal tissues by silver alloy metals in rats. J. Jpn. Assoc. Periodontal. Res. 31:1021-1046, 1989.
88. Wen HC, Lin YN, Ran SR, Tseng SC, Weng MX, Li YP, Lee PT, Chen PY, Hsu RQ, Wu WF, Chou CP: Observation of growth of human fibroblasts on silver nanoparticles. J. Phys. Conf. Ser. 61:445-449, 2007.
89. Westhofen M, Schafer H: Generalized argyrosis in man: neurotological, ultrastructural and X-ray microanalytical findings. Arch. Otorhinolaryngol. 243:260-264, 1986.
90. White JML, Powell AM, Brady K, Russell-Jones R: Severe generalized argyria secondary to ingestion of colloidal silver protein, Clin. Exp. Dermatol. 28:254-256, 2003.
91. Williams N, Gardner I: Absence of symptoms in silver refiners with raised blood silver levels. Occup. Med. 45:205-208, 1995.
92. Wood CM, Playle RC, Hogstrand C: Physiology and modelling of mechanisms of silver uptake and toxicity in fish. Environ. Toxicol. Chem. 18:71-81 1999.
93. Xia T, Kovochich M, Brant J, Hotze M, Sempf J, Oberley T, Sioutas C, Yeh JI, Wiesner MR, Nel AE: Comparision of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Lett. 8:1794-1807, 2006.
94. Zhang Y, Sun J: A Study on the bio-safety for nano-silver as anti-bacterial materials. Chin. J. Med. Instrum. 31:35-38, 2007b.
95. Zhang Y, Chen F, Zhuang J: Synthesis of silver nanoparticles via electrochemical reduction on compact zeolite film modified electrodes. Chem. Commun. (Camb.) 7:2814-2815, 2002.